TY - JOUR
T1 - The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs
AU - Hasegawa, Naoki
AU - Oka, Yoshio
AU - Nakayama, Mitsuo
AU - Berry, Gerald J.
AU - Bursten, Stuart
AU - Rice, Glenn
AU - Raffin, Thomas A.
PY - 1997
Y1 - 1997
N2 - The effects of lisofylline [(R)-1-(5-hydroxyhexyl)-3,7- dimethylxanthine] (LSF), an inhibitor of de novo phosphatidic acid (PA) generation, on sepsis-induced acute lung injury was studied using Hanford minipigs weighing 18 to 25 kg. Sepsis was induced by an intravenous infusion of Pseudomonas aeruginosa (1 x 106/colony-forming units/kg/min over 2 h). Saline was used as the control vehicle. Six groups were studied: saline control group (SALINE: n = 5); sepsis control group (SEPSIS: n = 5); LSF control group (LSF: n = 5), which received a 25-mg/kg bolus of LSF 30 min before time zero followed by continuous infusion of 10 mg/kg/h throughout the study; LSF-treated septic groups, which were treated with LSF 30 min prior to sepsis (Pre: n = 5), 1 h postonset (Post-1 h: n = 8) or 2 h postonset (Post- 2 h: n = 8) of the bacterial infusion, Hemodynamics, PA(O2), neutrophil counts, and plasma porcine tumor necrosis factor-α concentrations were monitored for 6 h. After the minipigs were killed, lung tissue was sampled to measure wet-to-dry weight ratio (W/D), tissue albumin index (TAI), thiobarbituric acid-reactive material content (TBARM), and myeloperoxidase (MPO) activity. Compared with the SALINE group, the SEPSIS group showed significant systemic hypotension, pulmonary hypertension, arterial hypoxemia, neutropenia, and increase in TNF-α, MPO activity, W/D, TBARM, and TAI. LSF treatment attenuated sepsis-induced pulmonary hypertension, neutropenia, and hypoxemia, and increased MPO activity and lung injury measurements in the Pre and Post-1 h groups, but its efficacy was blunted in the Post-2 h group. Plasma TNF-α was decreased only in the Pre group. Thus, inhibition of intracellular PA generation through de novo pathways attenuates sepsis- induced acute lung injury.
AB - The effects of lisofylline [(R)-1-(5-hydroxyhexyl)-3,7- dimethylxanthine] (LSF), an inhibitor of de novo phosphatidic acid (PA) generation, on sepsis-induced acute lung injury was studied using Hanford minipigs weighing 18 to 25 kg. Sepsis was induced by an intravenous infusion of Pseudomonas aeruginosa (1 x 106/colony-forming units/kg/min over 2 h). Saline was used as the control vehicle. Six groups were studied: saline control group (SALINE: n = 5); sepsis control group (SEPSIS: n = 5); LSF control group (LSF: n = 5), which received a 25-mg/kg bolus of LSF 30 min before time zero followed by continuous infusion of 10 mg/kg/h throughout the study; LSF-treated septic groups, which were treated with LSF 30 min prior to sepsis (Pre: n = 5), 1 h postonset (Post-1 h: n = 8) or 2 h postonset (Post- 2 h: n = 8) of the bacterial infusion, Hemodynamics, PA(O2), neutrophil counts, and plasma porcine tumor necrosis factor-α concentrations were monitored for 6 h. After the minipigs were killed, lung tissue was sampled to measure wet-to-dry weight ratio (W/D), tissue albumin index (TAI), thiobarbituric acid-reactive material content (TBARM), and myeloperoxidase (MPO) activity. Compared with the SALINE group, the SEPSIS group showed significant systemic hypotension, pulmonary hypertension, arterial hypoxemia, neutropenia, and increase in TNF-α, MPO activity, W/D, TBARM, and TAI. LSF treatment attenuated sepsis-induced pulmonary hypertension, neutropenia, and hypoxemia, and increased MPO activity and lung injury measurements in the Pre and Post-1 h groups, but its efficacy was blunted in the Post-2 h group. Plasma TNF-α was decreased only in the Pre group. Thus, inhibition of intracellular PA generation through de novo pathways attenuates sepsis- induced acute lung injury.
UR - http://www.scopus.com/inward/record.url?scp=0030953981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030953981&partnerID=8YFLogxK
U2 - 10.1164/ajrccm.155.3.9117028
DO - 10.1164/ajrccm.155.3.9117028
M3 - Article
C2 - 9117028
AN - SCOPUS:0030953981
VL - 155
SP - 928
EP - 936
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
SN - 1073-449X
IS - 3
ER -